Q-omics provides the consensus-scored PDZD11 profile across patient tissues and cancer cell-line models. PDZD11 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PDZD11 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PDZD11 protein abundance shows 18,625 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, KIRC, and LUAD as cancer lineages where PDZD11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDZD11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDZD11 survival associations across molecular data types. PDZD11 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDZD11 RNA expression–survival associations across cancer types. High PDZD11 expression shows unfavorable associations in UVM, HNSC, KICH, PAAD, ESCA and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PDZD11 RNA expression.
This table summarizes PDZD11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PDZD11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDZD11 shows higher tumor expression in KIRC, HNSC, KIRP, LIHC, LUAD and BRCA. The KIRC box plot shows higher PDZD11 RNA expression in tumor versus normal tissue (log2 FC = +0.839, t-test p < 0.001).
This table shows molecular features associated with PDZD11 in patient tissues and cancer cell lines. In patient samples, PDZD11 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PDZD11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
